[go: up one dir, main page]

WO2009041666A1 - 葉酸修飾されたシクロデキストリン化合物、その製造方法、標的指向性薬物送達システム用の薬物送達剤、医薬組成物及び造影剤 - Google Patents

葉酸修飾されたシクロデキストリン化合物、その製造方法、標的指向性薬物送達システム用の薬物送達剤、医薬組成物及び造影剤 Download PDF

Info

Publication number
WO2009041666A1
WO2009041666A1 PCT/JP2008/067566 JP2008067566W WO2009041666A1 WO 2009041666 A1 WO2009041666 A1 WO 2009041666A1 JP 2008067566 W JP2008067566 W JP 2008067566W WO 2009041666 A1 WO2009041666 A1 WO 2009041666A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug delivery
agent
folic acid
production
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/067566
Other languages
English (en)
French (fr)
Inventor
Kenjiro Hattori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanodex Inc
Original Assignee
Nanodex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanodex Inc filed Critical Nanodex Inc
Priority to US12/679,516 priority Critical patent/US8222400B2/en
Priority to EP08833790.2A priority patent/EP2194068B1/en
Priority to JP2009534446A priority patent/JP5597396B2/ja
Priority to CN2008801093523A priority patent/CN101809039B/zh
Publication of WO2009041666A1 publication Critical patent/WO2009041666A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0404—X-ray contrast preparations containing barium sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1268—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules host-guest, closed hollow molecules, inclusion complexes, e.g. with cyclodextrins, clathrates, cavitates, fullerenes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

　シクロデキストリンを構成するグルコピラノースの６位の第１級水酸基の２個以上が、それぞれ、葉酸を有する置換基で置換されてなるシクロデキストリン化合物。
PCT/JP2008/067566 2007-09-28 2008-09-26 葉酸修飾されたシクロデキストリン化合物、その製造方法、標的指向性薬物送達システム用の薬物送達剤、医薬組成物及び造影剤 Ceased WO2009041666A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/679,516 US8222400B2 (en) 2007-09-28 2008-09-26 Cyclodextrin compound modified with folic acid, process for production thereof, drug delivery agent for targeting drug delivery system, pharmaceutical composition, and imaging agent
EP08833790.2A EP2194068B1 (en) 2007-09-28 2008-09-26 Cyclodextrin compound modified with folic acid, process for production thereof, drug delivery agent for targeting drug delivery system, pharmaceutical composition, and imaging agent
JP2009534446A JP5597396B2 (ja) 2007-09-28 2008-09-26 葉酸修飾されたシクロデキストリン化合物、その製造方法、標的指向性薬物送達システム用の薬物送達剤、医薬組成物及び造影剤
CN2008801093523A CN101809039B (zh) 2007-09-28 2008-09-26 叶酸修饰的环糊精化合物、其制备方法、靶向性药物传递系统用的药物传递剂、药物组合物及造影剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007256527 2007-09-28
JP2007-256527 2007-09-28

Publications (1)

Publication Number Publication Date
WO2009041666A1 true WO2009041666A1 (ja) 2009-04-02

Family

ID=40511546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/067566 Ceased WO2009041666A1 (ja) 2007-09-28 2008-09-26 葉酸修飾されたシクロデキストリン化合物、その製造方法、標的指向性薬物送達システム用の薬物送達剤、医薬組成物及び造影剤

Country Status (5)

Country Link
US (1) US8222400B2 (ja)
EP (1) EP2194068B1 (ja)
JP (1) JP5597396B2 (ja)
CN (1) CN101809039B (ja)
WO (1) WO2009041666A1 (ja)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011190341A (ja) * 2010-03-15 2011-09-29 Nano Dex Kk シクロデキストリン化合物
US20120190057A1 (en) * 2009-05-19 2012-07-26 Onkotec Gmbh Method for the qualitative and/or quantitative analysis of tumour cells
WO2013022052A1 (ja) * 2011-08-11 2013-02-14 学校法人日本歯科大学 医療用薬剤および新規薬剤探索方法
WO2013147301A1 (ja) * 2012-03-30 2013-10-03 宇部興産株式会社 ブロック基を有するポリロタキサンの製造方法
WO2014045921A1 (ja) * 2012-09-19 2014-03-27 住友精化株式会社 ポリロタキサンの製造方法
JP2014531411A (ja) * 2011-08-22 2014-11-27 メルク・アンド・コンパニー １８ｆ−糖−ホラート
JP2015044961A (ja) * 2013-08-29 2015-03-12 学校法人同志社 シクロデキストリン誘導体及び医薬組成物
JP2016069520A (ja) * 2014-09-30 2016-05-09 ナノデックス株式会社 改良型葉酸修飾シクロデキストリン誘導体
JP2021181573A (ja) * 2017-03-02 2021-11-25 国立大学法人大阪大学 ホスト基含有重合性単量体、高分子材料及びその製造方法、並びに、包接化合物及びその製造方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102220128B (zh) * 2011-04-21 2013-08-21 江苏迈健生物科技发展有限公司 一种氨基化法β-环糊精修饰的低毒性功能化量子点及其制备方法
JP2014001204A (ja) * 2012-05-23 2014-01-09 Kumamoto Univ 腫瘍細胞選択的抗がん剤
CN104383555B (zh) * 2014-12-09 2018-05-22 中国人民解放军军事医学科学院毒物药物研究所 叶酸-环糊精偶联物、药物递送载体、制备方法及用途
WO2017059547A1 (en) * 2015-10-07 2017-04-13 Uti Limited Partnership Multifunctional polyanionic cyclodextrin dendrimers
CN107233314B (zh) * 2017-05-08 2020-09-18 荆楚理工学院 一种具有双靶区同时递药效果的复合磷脂热敏脂质体及其制备方法和应用
CN108047355A (zh) * 2017-12-22 2018-05-18 佛山科学技术学院 双叶酸修饰的β-环糊精及其合成方法和应用
CN113398112A (zh) * 2021-06-17 2021-09-17 西南医科大学 FA介导的BBA/CM-β-CD靶向递药系统、制备方法及其应用
CN113616813B (zh) * 2021-10-11 2021-12-21 奥信阳光(北京)药业科技有限公司 一种布洛芬与没食子酸改性磺丁基倍他环糊精钠的包合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502301A (ja) * 2002-09-06 2006-01-19 インサート セラピューティクス インコーポレイテッド 治療剤配送のためのシクロデキストリン基材重合体
JP2007256527A (ja) 2006-03-22 2007-10-04 Yamaha Corp 波形合成装置およびプログラム

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
CA2818071C (en) * 2002-09-06 2015-08-18 Cerulean Pharma Inc. Modified cyclodextrin ring compounds having exactly two hydroxyl moieties substituted with an amino acid for therapeutics delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502301A (ja) * 2002-09-06 2006-01-19 インサート セラピューティクス インコーポレイテッド 治療剤配送のためのシクロデキストリン基材重合体
JP2007256527A (ja) 2006-03-22 2007-10-04 Yamaha Corp 波形合成装置およびプログラム

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
AOKI, R. ARAI; K. HATTORI, J. INCLUSION PHENOM., vol. 50, 2004, pages 115 - 120
CALICETI, P. ET AL.: "Synthesis and Physicochemical Characterization of Folate- Cyclodextrin Bioconjugate for Active Drug Delivery", BIOCONJUGATE CHEM, vol. 14, no. 5, 2003, pages 899 - 908, XP001170950 *
K. HATTORI; A. KENMOKU; T. MIZUGUCHI; D. IKEDA; M. MIZUNO; T. INAZU, J. INCLUSION PHENOM. MACROCYCLIC CHEM., vol. 56, 2006, pages 9 - 16
K. HATTORI; A. KENMOKU; T. MIZUGUCHI; D. IKEDA; M. MIZUNO; T. INAZU, J. INCLUSION PHENOM. MACROCYCLIC CHEMISTRY, vol. 56, 2006, pages 9 - 16
M. KUNISHIMA; C. KAWACHI; J. MORITA; K. TERAO; F. IWASAKI; S. TANI, TETRAHEDRON, vol. 55, 1999, pages 13159 - 13170
P. CALICETI; S. SALMASO; A, SEMENZATO; T. CAROFIGLIO; R. FORNASIER; M. FERINEGLIA; M. FERRONE; S. PRICL, BIOCONJUGATE CHEM., vol. 14, 2003, pages 899 - 908
P. CALICETI; S. SALMASO; A, SEMENZATO; T. CAROFIGLIO; R. FORNASIER; M. FERMEGLIA; M. FERRONE; S. PRICL, BIOCONJUATE CHEM., vol. 14, 2003, pages 899 - 908
PHILIP S. LOW; WAITER A. HENNE; DEREK D. DOOMEWEERD, ACCOUNTS CHEM. RESEARCH, vol. 41, 2008, pages 120 - 129
PHILIP S. LOW; WALTER A. HENNE; DEREK D. DOOMEWEERD, ACCOUNTS CHEM. RESEARCH, vol. 41, 2008, pages 120 - 129
S. SALMASO; A. SEMENZATO; P. CALICETI; J. HOEBEKE; F.SONVICO; C.DUBERNET; P. COUVREUR, BIOCONJUGATE CHEM., vol. 15, 2004, pages 997 - 1004
S. WANG; PHILIP S. LOW, J. CONTROL. RELEASE, vol. 53, 1998, pages 39 - 48
S.SALMASO; S. SARA; A. SEMENZATO; P. CALICETI, J. DRUG TARGETING, vol. 15, no. 6, 2007, pages 379 - 390
SALMASO, S. ET AL.: "Specific Antitumor Targetable p-Cyclodextrin-Poly(ethylene Glycol) -Folic Acid Drug Delivery Bioconjugate", BIOCONJUGATE CHEM, vol. 15, no. 5, 2004, pages 997 - 1004, XP008131939 *
See also references of EP2194068A4
Y C. LEE; R. T. LEE, ACC. CHEM. RES, vol. 28, 1995
Z. LUKA; S. PAKHOMOVA; L. V. LOUKACHEVITCH; M. EGLI; M. E. NEWCOMER; C. WAGNER, J. BIOL. CHEM., vol. 282, 2007, pages 4069 - 4075

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120190057A1 (en) * 2009-05-19 2012-07-26 Onkotec Gmbh Method for the qualitative and/or quantitative analysis of tumour cells
JP2011190341A (ja) * 2010-03-15 2011-09-29 Nano Dex Kk シクロデキストリン化合物
WO2013022052A1 (ja) * 2011-08-11 2013-02-14 学校法人日本歯科大学 医療用薬剤および新規薬剤探索方法
JP2013040109A (ja) * 2011-08-11 2013-02-28 Nippon Dental Univ 医療用薬剤および新規薬剤探索方法
US9333266B2 (en) 2011-08-11 2016-05-10 The Nippon Dental University Medicinal agent for medical applications
JP2014531411A (ja) * 2011-08-22 2014-11-27 メルク・アンド・コンパニー １８ｆ−糖−ホラート
WO2013147301A1 (ja) * 2012-03-30 2013-10-03 宇部興産株式会社 ブロック基を有するポリロタキサンの製造方法
JPWO2013147301A1 (ja) * 2012-03-30 2015-12-14 宇部興産株式会社 ブロック基を有するポリロタキサンの製造方法
JP5604610B2 (ja) * 2012-09-19 2014-10-08 住友精化株式会社 ポリロタキサンの製造方法
KR20150058290A (ko) * 2012-09-19 2015-05-28 스미또모 세이까 가부시키가이샤 폴리로탁산의 제조 방법
WO2014045921A1 (ja) * 2012-09-19 2014-03-27 住友精化株式会社 ポリロタキサンの製造方法
US9487630B2 (en) 2012-09-19 2016-11-08 Sumitomo Seika Chemicals Co., Ltd. Method for manufacturing polyrotaxane
KR102049137B1 (ko) 2012-09-19 2020-01-08 스미또모 세이까 가부시키가이샤 폴리로탁산의 제조 방법
JP2015044961A (ja) * 2013-08-29 2015-03-12 学校法人同志社 シクロデキストリン誘導体及び医薬組成物
JP2016069520A (ja) * 2014-09-30 2016-05-09 ナノデックス株式会社 改良型葉酸修飾シクロデキストリン誘導体
JP2021181573A (ja) * 2017-03-02 2021-11-25 国立大学法人大阪大学 ホスト基含有重合性単量体、高分子材料及びその製造方法、並びに、包接化合物及びその製造方法
US12054571B2 (en) 2017-03-02 2024-08-06 Osaka University Host-group-containing polymerizable monomer, polymer material, method for producing same, and clathrate compound and method for producing same

Also Published As

Publication number Publication date
EP2194068B1 (en) 2013-04-17
EP2194068A4 (en) 2012-01-04
EP2194068A1 (en) 2010-06-09
JP5597396B2 (ja) 2014-10-01
US20100209347A1 (en) 2010-08-19
CN101809039A (zh) 2010-08-18
JPWO2009041666A1 (ja) 2011-01-27
US8222400B2 (en) 2012-07-17
CN101809039B (zh) 2012-08-29

Similar Documents

Publication Publication Date Title
WO2009041666A1 (ja) 葉酸修飾されたシクロデキストリン化合物、その製造方法、標的指向性薬物送達システム用の薬物送達剤、医薬組成物及び造影剤
WO2010008582A3 (en) Phagocytic cell delivery of rnai
WO2009121039A3 (en) Administration of benzodiazepine compositions
WO2008138755A3 (en) Pharmaceutical compositions for poorly soluble drugs
BR112012028291A2 (pt) composições farmacêuticas e métodos para sua produção
WO2009039262A3 (en) Steroid containing ophthalmic drug delivery systems
EP4327867A3 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
WO2010031720A3 (en) Novel antibody formulation
JO3757B1 (ar) التركيبات الصيدلانية التي تشمل على نيلوتينيب أو أملاحه
WO2011110939A3 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
WO2010122385A8 (fr) Formulation a action rapide d'insuline
WO2009130602A9 (en) Factor ix conjugates with extended half-lives
WO2010151644A3 (en) Antineoplastic hydrogels, and enzyme-instructed preparations thereof
WO2011159161A3 (en) Boronated polymers
WO2011023367A3 (en) Bisphosphonate-prodrugs
WO2009047321A3 (en) A sublingual effervescent tablet of progesterone associated with cyclodextrin
EP4101860A4 (en) HYALURONIC ACID DERIVATIVE, PHARMACEUTICAL COMPOSITION AND MEDICINE CONJUGATE - HYALURONIC ACID DERIVATIVE -
EP2131849A4 (en) COMPOSITIONS AND METHODS OF DISTRIBUTING AGENTS AGAINST CANCER
WO2011036357A3 (fr) Formulation liquide, stable, prete a l'emploi de ketoprofene
WO2007083190A8 (en) Water insoluble helichrysum extract, process for preparing the same and uses thereof
WO2012035561A3 (en) Improved oral targetted drug delivery system
WO2009051417A3 (en) Phenanthrene lactam derivatives having anticancer activity and method for the preparation thereof
WO2007097888A3 (en) Fluoroquinolone carboxylic acid salt compositions
WO2011056702A3 (en) Fast dissolving/disintegrating coating compositions
WO2011130716A3 (en) A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880109352.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08833790

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009534446

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12679516

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2008833790

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE